Skip to main content
SpringerLink
Log in

Skin-Related Complications of Insulin Therapy

Epidemiology and Emerging Management Strategies

  • Leading Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

The incidence and prevalence of all types of diabetes mellitus is increasing at an alarming rate. Modern therapy involves greater and earlier use of intensive insulin regimens in order to achieve better control of blood glucose levels and reduce the long-term risks associated with the condition. Insulin therapy is associated with important cutaneous adverse effects, which can affect insulin absorption kinetics causing glycemic excursions above and below target levels for blood glucose.

Common complications of subcutaneous insulin injection include lipoatrophy and lipohypertrophy. The development of lipoatrophy may have an immunological basis, predisposed by lipolytic components of certain insulins. Repeated use of the same injection site increases the risk of lipoatrophy — with time, patients learn that these areas are relatively pain free and continue to use them. However, the absorption of insulin from lipoatrophic areas is erratic leading to frequent difficulties in achieving ideal blood glucose control. With the increasing use of modified, rapidly absorbed analog insulins (e.g. insulin lispro, insulin aspart) the incidence of lipoatrophy occurring has decreased over recent years. The likelihood of lipoatrophy can be reduced by regular rotation of injection sites but once developed, practical benefits may be obtained by insulin injection into the edge of the area, co-administration of dexamethasone with insulin, or changing the mode of insulin delivery.

Lipohypertrophy is the most common cutaneous complication of insulin therapy. Newer insulins have also reduced its prevalence considerably, although its adverse effect on diabetic control is similar to lipoatrophy through impaired absorption of insulin into the systemic circulation. Experience with liposuction at these sites is limited, although good cosmetic results have been achieved.

Local allergic reactions to insulin are usually erythema, pruritus, and induration. These allergic reactions are usually short-lived, and resolve spontaneously within a few weeks. Useful adjuncts to managing allergic reactions include addition of dexamethasone to the insulin injection, desensitization to insulin, or a change in delivery system utilizing insulin pump therapy or potentially inhaled insulins when these become available. The use of insulin pump therapy in managing cutaneous complications of insulin therapy is increasing, but this method itself carries risks of abscess formation and scarring. Fortunately, with improved education of patients these are relatively uncommon.

Although many of the cutaneous manifestations are decreasing with the use of newer insulins, they may still influence glycemic control and increase the risk of hypoglycemia as well as have a cosmetic impact on a patient. The introduction of novel therapies and newer delivery systems is likely to reduce the cutaneous problems associated with long-term insulin use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Scherbaum WA. Insulin therapy in Europe. Diabetes Metab Res Rev 2002; 18 Suppl. 3: S50–6

    Article  Google Scholar 

  2. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the US: 1990–1998. Diabetes Care 2000; 23 (9): 1278–83

    Article  PubMed  CAS  Google Scholar 

  3. Centers for Disease Control and Prevention. Diabetes trends: diabetes and gestational diabetes trends among adults in the United States, behavioral risk factor surveillance system, 1995 [online]. Available from URL: http://www.cdc.gov/diabetes/statistics/maps/map6.htm [Accessed 23 July 2003]

  4. Centers for Disease Control and Prevention. Diabetes trends: diabetes and gestational diabetes trends among adults in the United States, behavioral risk factor surveillance system, 2000 [online]. Available from URL: http://www.cdc.gov/diabetes/statistics/maps/map9.htm [Accessed 23 July 2003]

  5. Wilson RM, Douglas CA, Tatershall RB, et al. Immunogenicity of highly purified bovine insulin: a comparison with conventional bovine and highly purified human insulins. Diabeologia 1985; 28: 667–70

    Article  CAS  Google Scholar 

  6. McNally PG, Jowett NI, Kurinczuk JJ, et al. Lipohypertrophy and lipoatrophy complicating treatment with highly purified bovine and porcine insulins. Postgrad Med J 1988; 64 (757): 850–3

    Article  PubMed  CAS  Google Scholar 

  7. Murao S, Hirata K, Ishida T, et al. Lipoatrophy induced by recombinant human insulin injection. Intern Med 1998; 37 (12): 1031–3

    Article  PubMed  CAS  Google Scholar 

  8. Mu L, Goldman JM. Human recombinant DNA insulin-induced lipoatrophy in a patient with type 2 diabetes mellitus. Endocr Pract 2000; 6 (2): 151–2

    PubMed  CAS  Google Scholar 

  9. Griffin ME, Feder A, Tamborlane WV. Lipoatrophy associated with lispro insulin in insulin pump therapy [letter]. Diabetes Care 2001; 24: 174

    Article  PubMed  CAS  Google Scholar 

  10. Edidin DV. Cutaneous manifestations of diabetes mellitus in children. Pediatr Dermatol 1985; 2: 161–79

    Article  PubMed  CAS  Google Scholar 

  11. Reeves WG, Allen BR, Tatershall RB. Insulin-induced lipoatrophy: evidence for an autoimmune pathogenesis. BMJ 1980; 1: 1500–3

    Article  Google Scholar 

  12. Raile K, Noelle V, Landgraf R, et al. Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes 2001; 109 (8): 393–6

    Article  PubMed  CAS  Google Scholar 

  13. Valenta LJ, Elias AN. Insulin induced lipodystrophy in diabetic patients resolved by treatment with human insulin. Ann Intern Med 1985; 102: 790–1

    PubMed  CAS  Google Scholar 

  14. Galloway JA, Bressler R. Insulin treatment in diabetes. Med Clin North Am 1978; 1: 983–8

    Google Scholar 

  15. Kumar D, Miller L, Mehtalia S. Use of dexamethasone in treatment of insulin lipodystrophy. Diabetes 1977; 26: 296–9

    Article  PubMed  CAS  Google Scholar 

  16. Chantelau E, Reuter M, Schotes S, et al. Severe lipoatrophy with human insulin: successfully treated by CSII. Diabet Med 1993; 10 (6): 580–1

    Article  PubMed  CAS  Google Scholar 

  17. Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes 1996; 104 (2): 106–10

    Article  PubMed  CAS  Google Scholar 

  18. Young RJ, Hannan WT, Frier BM, et al. Diabetic Lipohypertrophy delays insulin absorption. Diabetes Care 1984; 7: 479–80

    Article  PubMed  CAS  Google Scholar 

  19. Turner BC, Heijlesen OK, Kerr D, et al. Impaired absorption and omission of insulin: a novel method of detection using the diabetes advisory system computer model. Diabetes Technol Ther 2001; 3 (1): 99–109

    Article  PubMed  CAS  Google Scholar 

  20. Roper NA, Bilous RW. Resolution of lipohypertrophy following change of short-acting insulin to insulin lispro. Diabet Med 1998; 15 (12): 1063–4

    Article  PubMed  CAS  Google Scholar 

  21. Samdal F, Amland PF, Sandsmark M, et al. Diabetic lipohypertrophy treated with suction-assisted lipectomy. J Intern Med 1993; 234 (5): 489–92

    Article  PubMed  CAS  Google Scholar 

  22. Galloway JA, Fireman P, Fineberg SE. Complications of insulin therapy: a brief review of four years experience with human insulin (rDNA). In: Church J, editor. Diabetes mellitus: achievements and scepticism. Royal Society of Medicine International Congress and Symposium series, vol 77. Oxford: Oxford University Press, 1984: 55–64

    Google Scholar 

  23. Grammer L. Insulin allergy. Clin Rev Allergy 1986; 4: 189–200

    PubMed  CAS  Google Scholar 

  24. Granic M, Renar IP, Metelko Z, et al. Insulin allergy. Diabetes Care 1986; 9: 99–100

    PubMed  CAS  Google Scholar 

  25. Menoscal A, Lavarello A, Garcia de los Rios M. Anaphylactic shock due to highly purifies porcine insulin. Rev Med Chil 1986; 114 (10): 969–72

    PubMed  CAS  Google Scholar 

  26. Soto-Aguilar MC, de-Shazo RD, Waning NP. Anaphylaxis. Postgrad Med 1987; 82: 154–70

    PubMed  CAS  Google Scholar 

  27. Fireman P, Fineberg SE, Galloway JA. Development of IgE antibodies to human (recombinant DNA), porcine and bovine insulins in diabetic subjects. Diabetes Care 1982; 5 (2): 119–25

    PubMed  Google Scholar 

  28. Kumar D, Rosenquist RJ, Parameswaran V. Insulin allergy: reaginic antibodies to insulin and pro-insulin. J Clin Endocrinol Metab 1979; 49: 252–4

    Article  PubMed  CAS  Google Scholar 

  29. Feinglos MN, Jegasothy BV. “Insulin” allergy due to zinc. Lancet 1979; I (8108): 122–4

    Article  Google Scholar 

  30. Lee AY, Chey WY, Choi J, et al. Insulin-induced drug eruptions and reliability of skin tests. Acta Derm Venereol 2002; 82 (2): 114–7

    Article  PubMed  Google Scholar 

  31. Dykewicz MS, Kim HW, Orfan N, et al. Immunologic analysis of anaphylaxis to protamine component in neutral protamine Hagedorn human insulin. J Allergy Clin Immunol 1994; 93 (1): 117–25

    Article  PubMed  CAS  Google Scholar 

  32. Bollinger ME, Hamilton RG, Wood RA. Protamine allergy as a complication of insulin hypersensitivity: a case report. J Allergy Clin Immunol 1999; 194 (2): 462–5

    Article  Google Scholar 

  33. DeShazo RD, Boehm TM, Kumar D, et al. Dermal hypersensitivity reactions to insulin: correlations of three patterns to their histology. J Allergy Clin Immunol 1982; 69: 229–37

    Article  PubMed  CAS  Google Scholar 

  34. Takata H, Kumon Y, Osaki F, et al. The human insulin analogue aspart is not the almighty solution for insulin allergy. Diabetes Care 2003; 26 (1): 253–4

    Article  PubMed  Google Scholar 

  35. Yasuda H, Nagata M, Moriyama H, et al. Human insulin analog insulin aspart does not cause insulin allergy. Diabetes Care 2001; 24 (11): 2008–9

    Article  PubMed  CAS  Google Scholar 

  36. Grammer LC, Chen PY, Patterson R. Evaluation and management of insulin allergy. J Allergy Clin Immunol 1983; 71: 250–4

    Article  PubMed  CAS  Google Scholar 

  37. Witters LE, Ottman JL, Weir GC, et al. Insulin antibodies in the pathogenesis of insulin allergy and resistance. Am J Med 1977; 63: 703–9

    Article  PubMed  CAS  Google Scholar 

  38. Pratt EJ, Miles P, Kerr D. Localized insulin allergy treated with continuous subcutaneous insulin. Diabet Med 2001; 18: 514–6

    Article  Google Scholar 

  39. Naf S, Esmatjes E, Reccasens M, et al. Continuous subcutaneous insulin infusion to resolve an allergy to human insulin. Diabetes Care 2002; 25 (3): 634–5

    Article  PubMed  Google Scholar 

  40. DCCT Research Group. Diabetes Control and Complications Trial (DCCT): the effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86

    Article  Google Scholar 

  41. Boland EA, Grey M, Oesterle A, et al. A “new” way to lower risk of severe hypoglycaemia, improve metabolic control and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999; 22: 1779–84

    Article  PubMed  CAS  Google Scholar 

  42. Van Faassen, Razenberg PPA, Simoons-Smit AM, et al. Carriage of staphylococcus aureus and inflamed infusion sites with insulin pump therapy. Diabetes Care 1989; 12: 153–5

    Article  PubMed  Google Scholar 

  43. Guinn TS, Bailey GJ, Mecklenberg RS. Factors related to discontinuation of subcutaneous insulin infusion therapy. Diabetes Care 1988; 11: 46–51

    Article  PubMed  CAS  Google Scholar 

  44. Mecklenberg RS, Benson EA, Benson Jr JW, et al. Acute complications associated with insulin pump therapy: report of experience with 161 patients. JAMA 1984; 252: 3265–9

    Article  Google Scholar 

  45. Wickline CL, Cornitus TG, Butler T. Cellulitus caused by Rhizomucor pusillus in a diabetic patient receiving continuous insulin infusion pump therapy. Southern Med J 1989; 82: 1432–4

    Article  PubMed  CAS  Google Scholar 

  46. Chantelau E, Spraul M, Muhlhauser I, et al. Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for Type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetolgia 1989; 32: 421–6

    Article  CAS  Google Scholar 

  47. Chantelau E, Lange G, Sonnenberg GE, et al. Acute cutaneous complications and catheter needle colonization during insulin pump treatment. Diabetes Care 1987; 10: 478–82

    Article  PubMed  CAS  Google Scholar 

  48. Anderson JA, Adkinson NF. Allergic reactions to drugs and biologic agents. JAMA 1987; 258: 2891–9

    Article  PubMed  CAS  Google Scholar 

  49. Swift B, Hawkins PN, Richards C, et al. Examination of insulin injection sites: an unexpected finding of localized amyloidosis. Diabet Med 2002; 19: 881–2

    Article  PubMed  CAS  Google Scholar 

  50. Dische FE, Wernstedt C, Westermark GT, et al. Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient. Diabetologia 1988; 31: 158–61

    Article  PubMed  CAS  Google Scholar 

  51. Wheatley T, Edwards OM. Insulin oedema and its clinical significance: metabolic studies in three cases. Diabet Med 1985; 2: 400–4

    Article  PubMed  CAS  Google Scholar 

  52. Hopkins DFC, Cotton SJ, Williams G. Effective treatment of insulin-induced oedema using ephedrine. Diabetes Care 1993; 16: 1026–8

    Article  PubMed  CAS  Google Scholar 

  53. Skyler JS, Cefalu WT, Kourides IA, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001; 357: 331–5

    Article  PubMed  CAS  Google Scholar 

  54. Stoever JA, Palmer JP. Inhaled insulin and insulin antibodies: a new twist to an old debate. Diabetes Technol Ther 2002; 4 (2): 157–61

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript. We would like to thank the Royal Bournemouth Hospital Department of Medical Photography for their help in preparing the photos.

Author information

Authors and Affiliations

  1. Bournemouth Diabetes and Endocrine Centre, Royal Bournemouth Hospital, Castle Lane East, Bournemouth, BH7 7DW, UK

    Tristan Richardson & David Kerr

Authors
  1. Tristan Richardson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Kerr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tristan Richardson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Richardson, T., Kerr, D. Skin-Related Complications of Insulin Therapy. Am J Clin Dermatol 4, 661–667 (2003). https://doi.org/10.2165/00128071-200304100-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200304100-00001

Keywords

Search

Navigation